1Eaddy M, Grogg A,Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a medical population. Clin Ther. 2005; 27 (2): 263-272.
2Misdrahi D, Llorca PM, Lancon C, et al. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale. 2002; 28 (3): 266- 272.
3Glick ID, Berg PH. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders. Int CAin Psychopharmacol. 2002; 17 (2): 65-68.
4Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull. 21304; 30 (2): 255-264.
5Motlova L. Psychoeducation as an indispensable complement to phannacothempy in schizophrenia. Pharmacopsychiatry, 2000; 33 (Suppl 1 ) : 47-48.
6Bloch Y, Mendlovic S, Strupimky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt? J Clin Psychiatry, 2001; 62 (11): 855-859.
7Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med. 2003; 33 (1) : 83-89.
8Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an anfipsychotic: clinical studies. J Clin Psychiatry, 2003; 64 (Suppl 16) : 34-40.
9Stein R, Preisman O, Alfici S, et al. A long-acting second generation anti-psychotic-experience in Israel. Harefuah. 2004; 143 (6): 408-409.
10Edwards NC, Rupnow MF, Pashos CL, et al. Cost-effectiveness model of long-acting risperidone in schizophrenia in the US. Pharmacoeconomics, 2005; 23 (3): 299-314.
